Impact evaluation delay hurting pneumococcal conjugate vaccine scheme expansion
(WorldNews Health)

Government`s plan to expand coverage of Pneumococcal Conjugate Vaccine (PCV) that prevents pneumonia among children to all states by 2022 may face a delay as an valuation of the vaccine`s impact on citizens remains pending. Two years the ministry of health and family welfare rolled out PCV, the vaccine´s impact study is yet to start. The only evaluation study that was supposed to start in November 2018 and finish by July 2022 couldn´t take off due to technical reasons, government officials told Mint. `Sponsored by Johns Hopkins Bloomberg School of Public Health, the research titled -Evaluating the Impact of the PCV in India (INSPIRE)-was to be conducted by International Clinical Epidemiology...